Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of mRNA-1283 and mRNA-1273 Variant Vaccines for COVID-19
NCT07863635Phase 4Recruiting
- Sponsor
- Moderna Inc
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 4 trial of mNEXSPIKE, elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Oct 2026; status: recruiting.
02
Drugs
mNEXSPIKEelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07863635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863635.